High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients.

Abstract

COI Statement

N.G. Hammond reports grants from the NCI during the conduct of the study. R.B. Cameron reports personal fees from MJH Life Sciences outside the submitted work. A. Kaushik reports other support from Pfizer outside the submitted work. A.D. Rao reports other support from MSD outside the submitted work. J.D. Minna reports grants from the NCI during the conduct of the study and personal fees from the NIH and the University of Texas Southwestern Medical Center outside the submitted work. J. Waters reports personal fees from AstraZeneca outside the submitted work, and his wife is a paid consultant for Gore Medical and leads an industry-sponsored clinical trial in peripheral arterial disease. B. Faubert reports grants from the NCI and the Cancer Research Foundation during the conduct of the study. R.J. DeBerardinis reports personal fees from Agios Pharmaceuticals, Atavistik Bio, and Vida Ventures outside the submitted work. No disclosures were reported by the other authors.

References:

• Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab 2022;34:355–77.
• DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016;2:e1600200.
• Elia I, Doglioni G, Fendt SM. Metabolic hallmarks of metastasis formation. Trends Cell Biol 2018;28:673–84.
• Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science 2020;368:eaaw5473.
• Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020;11:102.